We read with great interest the recent Clinical and Molecular Hepatology study elucidating a novel MET-TRIB3-FOXO1 signaling axis that drives hepatocellular carcinoma (HCC) progression [1]. While the study is comprehensive, integrating in vitro, in vivo, and patient cohort analyses, it also raises several important questions that require further exploration and refinement to strengthen its translational impact.

First, the mechanistic finding that TRIB3 acts as an adapter to promote COP1-mediated degradation of the tumor suppressor FOXO1 significantly advances our understanding of HCC biology. However, additional validation is needed to confirm the directness and specificity of these protein-protein interactions in the endogenous cellular context, given the reliance on co-immunoprecipitation and mass spectrometry data. Previous studies have shown that E3 ligase–substrate recognition can be highly context-dependent, and co-immunoprecipitation may detect indirect interactions mediated by larger protein complexes [2]. Proximity ligation assays or cross-linking mass spectrometry could be employed to confirm direct binding between TRIB3, COP1, and FOXO1 within HCC cells to strengthen the mechanistic claims. Furthermore, identifying the specific residues that mediate these interactions would indicate whether the TRIB3-COP1 complex could be effectively targeted by small-molecule inhibitors, which is a promising approach for treating MET-driven HCC.

Second, the observation that TRIB3 upregulation is specifically mediated via the MET/ERK/SP1 axis provides a clear, clinically relevant signaling cascade. However, the study primarily focuses on ERK as the sole effector of TRIB3 induction. This leaves open questions about how other key MET downstream pathways, such as PI3K/AKT and JNK, might interact with this mechanism. PI3K/AKT signaling is well known to regulate FOXO1 nuclear localization and activity, and previous studies have demonstrated crosstalk between the ERK and AKT pathways in HCC progression [3]. Future work could incorporate the combined pharmacological inhibition of the ERK and PI3K/AKT pathways to determine if this approach has a synergistic effect on TRIB3 expression and HCC cell survival. Such experiments would also clarify whether dual-pathway blockade can overcome the compensatory feedback that has historically undermined the efficacy of MET inhibitors in clinical trials. This integrated perspective is essential for devising effective combinatorial therapies in HCC.

Third, the study’s in vivo models, particularly the hydrodynamic tail vein injection-based HCC mouse models, provide compelling evidence for the MET-TRIB3-FOXO1 axis in tumor growth and metastasis. However, these models may not fully recapitulate the immunosuppressive tumor microenvironment characteristic of advanced HCC in patients. Immune evasion is a hallmark of HCC progression, and MET has been associated with modulating the recruitment of immunosuppressive myeloid cells [4]. Investigating whether TRIB3 shapes the immune microenvironment by regulating the expression of cytokines or immune checkpoint molecules downstream of MET would be intriguing. Single-cell RNA sequencing or spatial transcriptomics on HCC tissues with manipulated TRIB3 levels could provide insight into these interactions. Such work would validate TRIB3’s role as a tumor-intrinsic driver and highlight its relevance as an immunomodulatory target, which is especially pertinent given the growing use of immune checkpoint inhibitors in HCC therapy.

In conclusion, this significant study unveils a novel, TRIB3-centric oncogenic pathway in HCC, opening several promising avenues for future research. Strengthening the biochemical characterization of TRIB3/COP1/FOXO1 interactions, analyzing compensatory signaling networks beyond ERK, and investigating the immunologic consequences of TRIB3 upregulation could collectively improve our understanding of this axis and hasten the development of effective HCC therapies.

Citations to this article as recorded by